Vaginal and sexual health in patients with ER+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Shanahan, Kelly [1 ]
Sammons, Sarah [2 ]
Meisel, Jane L. [3 ]
Pluard, Timothy J. [4 ]
Kozlowski, Monica [5 ]
Carroll, Dominic [5 ]
Attias, Elizabeth [5 ]
机构：
[1] Metavivor Res & Support Inc, Annapolis, MD USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Emory Winship Canc Inst, Atlanta, GA USA
[4] St Lukes Canc Inst, Kansas City, MO USA
[5] Sermonix Pharmaceut, Columbus, OH USA
来源：
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2023年 / 30卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
P-89
引用
下载
收藏
页码：1296 / 1296
页数：1
相关论文
共 50 条
  • [1] Treatment goals and quality of life (QOL) in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)
    Sammons, Sarah L.
    Meisel, Jane
    Shanahan, Kelly
    Pluard, Timothy
    Kozlowski, Monica
    Carroll, Dominic
    Attias, Elizabeth
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Targeted therapies for ER+/HER2-metastatic breast cancer
    Yamamoto-Ibusuki, Mutsuko
    Arnedos, Monica
    Andre, Fabrice
    BMC MEDICINE, 2015, 13
  • [3] Vaginal and vulvar symptoms in patients with ESR1-mutated, ER+/ HER2-metastatic breast cancer by baseline characteristics
    Goldfarb, Shari B.
    Sammons, Sarah
    Meisel, Jane L.
    Pluard, Timothy J.
    Jenkins, Simon N.
    Komm, Barry
    Carroll, Dominic
    Portman, David J.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2023, 30 (12): : 1278 - 1279
  • [4] BUDGET IMPACT ANALYSIS OF EVEROLIMUS FOR ER+, HER2-METASTATIC BREAST CANCER PATIENTS IN THE UNITED STATES
    Xie, J.
    Diener, M.
    De, G.
    Wu, E. Q.
    Namjoshi, M.
    VALUE IN HEALTH, 2012, 15 (04) : A212 - A212
  • [5] VAGINAL/VULVAR SYMPTOMS WITH LASOFOXIFENE VERSUS FULVESTRANT IN ESR1-MUTATED, ER+/HER2-METASTATIC BREAST CANCER PATIENTS
    Goldfarb, S. B.
    Sammons, S. L.
    Meisel, J. L.
    Pluard, T. J.
    Jenkins, S. N.
    Komm, B.
    Carroll, D.
    Portman, D. J.
    JOURNAL OF SEXUAL MEDICINE, 2023, 20
  • [6] Efficacy and safety of everolimus for heavily pretreated patients with ER+/HER2-metastatic breast cancer.
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Fujisue, Mamiko
    Yamada, Mitsuhiro
    Suko, Kyoko
    Morioka, Junko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2+or HER2-metastatic breast cancer
    Hunter, Natasha
    Peterson, Lanell M.
    Mankoff, David A.
    Muzi, Mark
    Chen, Delphine
    Gwin, William R.
    Vinayak, Shaveta
    Davidson, Nancy E.
    Specht, Jennifer M.
    Linden, Hannah
    CANCER RESEARCH, 2023, 83 (05)
  • [8] Knowledge of tumor/blood genomic testing (NGS) and ESR1 mutations in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)
    Meisel, Jane
    Sammons, Sarah L.
    Shanahan, Kelly
    Pluard, Timothy
    Kozlowski, Monica
    Carroll, Dominic
    Attias, Elizabeth
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2-metastatic breast cancer (mBC): the ELAINE 2 study
    Damodaran, Senthil
    Cristofanilli, Massimo
    Goetz, Matthew
    O'Sullivan, Ciara
    Riordan, Gary
    Rugo, Hope
    Stover, Daniel
    Wander, Seth
    Carroll, Dominic
    Plourde, Paul V.
    Portman, David J.
    Yam, Einav Nili-Gal
    CANCER RESEARCH, 2024, 84 (09)
  • [10] HER2 mutations detected by ctDNA in ER+/HER2-metastatic breast cancer patients: Incidence and impact on clinical outcomes
    Medford, Arielle
    Juric, Dejan
    Niemierko, Andrzej
    Malvarosa, Giuliana
    Park, Hannah
    Shellock, Maria
    Spring, Laura
    Moy, Beverly
    Isakoff, Steven
    Ellisen, Leif
    Bardia, Aditya
    CANCER RESEARCH, 2018, 78 (04)
12345